MS and Demyelinating Disorders

Mitzi Joi Williams, MD, is joined by Dietrich Cox, MD, and Sheree Love to discuss the causes, evaluation, and management of spasticity in neurologic conditions.

Tom Fuchs, MD, PhD, postdoctoral researcher at the MS Center at Amsterdam University Medical Center, shared his reaction to the European Commission's approval of tolebrutinib for nonrelapsing secondary progressive MS.

New findings suggest that monoclonal antibody therapy was associated with a 34% lower risk of relapse in patients with AQP4-IgG seropositive NMOSD compared with those who were seronegative.

Jens Kuhle, MD, PhD, head of the Multiple Sclerosis Centre at University Hospital Basel, discusses the EU approval of tolebrutinib for nonrelapsing SPMS and its implications for treating disability progression.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Grace Gombolay, MD; and Varun Kannan, MD. [LISTEN TIME: 25 minutes]

The European Commission has approved Cenrifki (tolebrutinib) for nrSPMS without relapses in the last two years, a milestone that arrives despite the drug's failed US submission and a regulatory pathway that has been anything but linear.

The professor of neurology at UT Southwestern Medical Center discussed the Octave Multiple Sclerosis Disease Activity Test as a complementary tool to MRI and clinical assessment in MS. [WATCH TIME: 6 minutes]

FDA’s clearance for PTD802, a first-in-class GPR17 antagonist designed to promote remyelination, enables initiation of a first-in-human phase 1 study in healthy volunteers and advances a novel regenerative approach for multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 19, 2026.

Maya Hrachova, DO, neurologist and neuro-oncologist at Allina Health Brain and Spine Institute, discusses the evolving role of neurologic consultation in cancer care and the importance of accurate diagnosis in complex oncology patients.

Mitzi Joi Williams, MD, sits down with Sheree Love and Mana Opang Owusu to discuss how movement supports brain health, function, and quality of life for people living with neurologic conditions.

Here's some of what is coming soon to NeurologyLive® this week.

Neurologists Sarah Simmons, MD, PhD, and Fatma Inanici, MD, PhD, discuss how the combination of noninvasive cervical spinal cord stimulation with exercise therapy can improve upper extremity function in people with MS.

The senior vice president for research at the Kessler Foundation discussed findings showing associations between reductions in neurofilament light chain and gains in cognitive processing speed, verbal memory, and visual memory in patients with early relapsing multiple sclerosis treated with ozanimod. [WATCH TIME: 3 minutes]

The new president of Consortium of Multiple Sclerosis Centers (CMSC) discussed key themes in multiple sclerosis care presented at the 2026 CMSC Annual Meeting. [WATCH TIME: 11 minutes]

Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.

Daniel Vitt, PhD, chief executive officer of Immunic, discussed the dual mechanism of vidofludimus calcium, ongoing phase 3 ENSURE trials in relapsing MS, and phase 2 CALLIPER findings suggesting potential neuroprotective effects in progressive MS.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 5, 2026.

As the MS community reflects on World MS Day, Alla Wilson, a clinical ambulatory pharmacist at Shields Health Solutions, discusses how integrated specialty pharmacy models can improve treatment access, adherence, and patient-reported outcomes for multiple sclerosis.

The assistant professor of neurology at NYU Grossman School of Medicine discussed how optical coherence tomography can support the 2024 McDonald Criteria for multiple sclerosis at CMSC 2026.

Kyle Blackburn, MD, a neurologist at UT Southwestern Medical Center, discussed new proposed updates to the diagnostic criteria and nosology for myelitis presented at the 2026 CMSC Annual Meeting.